1093 CLN-617 combines IL-2 and IL-12 in a single molecule to optimally balance safety and efficacy upon intratumoral injection

Abstract

BackgroundIL-2 and IL-12 synergistically mediate anti-tumor immunity but trigger severe adverse events. CLN-617 is comprised of IL-2, leukocyte-associated immunoglobulin-like receptor 2 (LAIR2), human serum albumin (HSA), and IL-12, and is...